# Study Measuring the Safety, Immunogenicity and Lot Consistency of Cell Derived Influenza Vaccine

> **NCT00999206** · PHASE3 · COMPLETED · sponsor: **Abbott Biologicals** · enrollment: 3138 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Influenza Vaccine
- **BIOLOGICAL:** Influenza Vaccine
- **BIOLOGICAL:** Influenza Vaccine
- **BIOLOGICAL:** Influenza Vaccine

## Key facts

- **NCT ID:** NCT00999206
- **Lead sponsor:** Abbott Biologicals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 3138 (ACTUAL)
- **Last updated:** 2011-08-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00999206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00999206, "Study Measuring the Safety, Immunogenicity and Lot Consistency of Cell Derived Influenza Vaccine". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00999206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*